Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
AMRX
AMRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AMRX News
Doseology Sciences Launches New Energy Product Line
2d ago
PRnewswire
Doseology Sciences Launches New Energy Product Line
2d ago
Newsfilter
Amneal Pharmaceuticals Settles Majority of Opioid Claims for Up to $267M
Jan 29 2026
seekingalpha
Healthcare Stocks Surge in After-Hours Trading
Jan 28 2026
NASDAQ.COM
Amneal Pharmaceuticals (AMRX) Expects to Meet or Exceed Expectations
Jan 13 2026
Yahoo Finance
Amneal Secures FDA Approval for Six Biosimilars by 2027
Dec 26 2025
Newsfilter
Amneal Receives FDA Approval for Two Biosimilars
Dec 23 2025
NASDAQ.COM
Amneal Receives FDA Approval for Six Biosimilars by 2027
Dec 22 2025
Globenewswire
Teva aims to eliminate more than 200 patents from the FDA Orange Book following FTC dispute.
Dec 10 2025
SeekingAlpha
Amneal Receives FDA Approval for Epinephrine Injection in Both Single and Multi-Dose Vials
Dec 10 2025
NASDAQ.COM
Amneal Receives FDA Approval for Epinephrine Injection, Expanding Injectable Portfolio
Dec 09 2025
Globenewswire
Amneal Receives FDA Approval for Epinephrine Injection, Expanding Injectable Portfolio
Dec 09 2025
Newsfilter
Amneal's CREXONT Therapy Significantly Improves Parkinson's Symptoms
Dec 05 2025
Globenewswire
Amneal Pharma Announces Encouraging Interim Findings from Ongoing Phase 4 ELEVATE-PD Trial
Dec 05 2025
NASDAQ.COM
Amneal Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol with $1.5B Market Potential
Dec 02 2025
Newsfilter
FDA Grants Approval for Amneal Pharma's Generic Version of RESTASIS for Treating Dry Eye Disease
Dec 02 2025
NASDAQ.COM
Show More News
